JPMorgan on Friday night downgraded Mereo BioPharma (MREO) to Neutral from Overweight without a price target The firm cites the uncertainty of the regulatory process for the company’s setrusumab program for the downgrade. The Phase 3 ORBIT and COSMIC trials of setrusumab in osteogenesis imperfecta missed their primary endpoints of annualized fracture rate, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MREO:
- Mereo BioPharma downgraded to Neutral from Overweight at JPMorgan
- Balanced Risk-Reward Amid Clinical Uncertainty: Maintaining Hold on Mereo BioPharma
- Mereo BioPharma repors FY25 EPS (5c), consenus (4c)
- Mereo BioPharma sees cash runway into mid-2027
- Mereo BioPharma Lawsuit Alleges Misleading Trial Claims After Setrusumab Study Failures